Navigation Links
Cell Therapeutics to Host Conference Call Today, Friday, November 15, 2013, at 8:30 a.m. Eastern Time, to Discuss Pacritinib Partnership
Date:11/15/2013

SEATTLE, Nov. 15, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that members of management will host a conference call today, Friday, November 15, 2013 at 8:30 a.m. ET (5:30 a.m. PT) to discuss today's announcement regarding the worldwide licensing agreement between Baxter International, Inc. and CTI to develop and commercialize pacritinib, CTI's novel investigational JAK2/FLT3 inhibitor currently in Phase 3 development for patients with myelofibrosis.  Access to the event can be obtained as follows:

Friday, November, 15, 2013
5:30 a.m. PT/8:30 a.m. ET/2:30 p.m. CET
1-800-762- 8779(domestic)
+1 480-629-9645 (international)

To access the live audio webcast or the subsequent archived recording, visit www.celltherapeutics.com. Webcast and telephone replays of the conference call will be available at approximately two hours after completion of the call. Callers can access the replay by dialing 1-800-406-7325 (domestic) or +1 303-590-3030 (international). The access code for the replay is 4651503. The telephone replay will be available until Friday, November 22, 2013.

About Cell Therapeutics, Inc.
Cell Therapeutics (NASDAQ and MTA: CTIC) is a biopharmaceutical company committed to the development and commercialization of an integrated portfolio of oncology products aimed at making cancer more treatable. CTI is headquartered in Seattle, WA. For additional information and to sign up for email alerts and get RSS feeds, please visit the company's website at www.CellTherapeutics.com.

Contacts:
Monique Greer
+1 206-272-4343
mgreer@ctiseattle.com

Ed Bell
+1 206.282.7100
ebell@ctiseattle.com

In Europe
CTI Life Sciences Limited, Milan Branch
Laura Villa
T: +39 02 89659706
E: lvilla@cti-lifesciences.com
CTI_EUInvestors@CTI-Lifesciences.com


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Signum Dermalogix Receives $1.6M Phase II SBIR Grant for the Development of Novel Atopic Dermatitis Therapeutics
2. PTC Therapeutics Reports Third Quarter 2013 Financial and Corporate Results
3. Aratana Therapeutics Reports Third Quarter 2013 Financial Results
4. Levi & Korsinsky, LLP Launches Investigation of SAREPTA THERAPEUTICS, INC. for Possible Violations of Federal Securities Laws
5. Argos Therapeutics to Present at the Elsevier Therapeutic Area Partnerships Meeting
6. Mirati Therapeutics Reports Third Quarter 2013 Financial Results
7. Sorrento Therapeutics Adopts Stockholder Rights Plan
8. Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2013
9. Shield Therapeutics Files Investigational New Drug Application for ST10 for the Treatment of Iron Deficiency in Chronic Kidney Disease
10. Cara Therapeutics Files Registration Statement for Proposed Initial Public Offering
11. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... Research and Markets has announced the addition of the ... ... analytics for the US, Canada , Japan ... Latin America , and Rest of World. Annual estimates ... six-year historic analysis is provided for these markets. Market data and analytics ...
(Date:2/17/2017)... , Feb. 17, 2017 Arvinas LLC, a ... based on protein degradation, today announced the presentation of ... PROTAC during a poster session at the American Society ... in Orlando, FL. ... our platform and the potential of PROTACs to drive ...
(Date:2/17/2017)...   Risperdal lawsuits involving gynecomastia (male breast growth) ... of the atypical antipsychotic medication continue to move forward ... Common Pleas, where the state,s Risperdal docket has been ... notice posted on the Court,s website , the ... 9, 2017 at 11:00 a.m. (In Re: Risperdal Litigation, ...
Breaking Medicine Technology:
(Date:2/20/2017)... PA (PRWEB) , ... February 20, 2017 , ... Researchers ... of thyroid cancer, as well as a marker that may predict response to a ... with many other types of cancer as well. The new findings were published in ...
(Date:2/20/2017)... ... 20, 2017 , ... The StayWell Company and VUCA Health ... patient health risks, foster behavior change and improve health literacy among patients. VUCA Health, ... a demonstration of its video capability at StayWell booth 3443 during HiMSS. , ...
(Date:2/20/2017)... (PRWEB) , ... February 20, 2017 , ... ... technology, welcomes you to stop by for a visit this week at HIMSS ... clinicians and executives from around the globe. Sensogram will be featured in the ...
(Date:2/20/2017)... Sunapee, NH (PRWEB) , ... February 20, 2017 , ... ReportingMD, a Population Health Software ... rapid growth of the company. The new location will triple the size of the ... location for the town of Sunapee, NH. , “We are excited to expand ...
(Date:2/20/2017)... ... February 20, 2017 , ... Johns Hopkins All Children's ... building. A topping out ceremony on Friday marked the halfway point of construction and ... open in Fall 2018, will serve as a center for innovation aimed at finding ...
Breaking Medicine News(10 mins):